ArticleNPJ precision oncology2026
Integrated analysis of radiomics and RNA reveals the biological basis and therapeutic implications of aggressive hepatocellular carcinoma subtypes.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The aggressive subtype of hepatocellular carcinoma (HCC) is associated with a poor prognosis, and histopathological biopsy is the current method used for its diagnosis and tumour microenvironment analysis. Hence, we constructed a radiomics-based artificial intelligence model with robust predictive performance and explored the underlying biological characteristics by analysing mRNA data. The predictive performance was validated in two external centres, yielding areas under the curve ranging from 0.79 to 0.84, and their ability to predict progression-free survival (PFS) was evaluated. Radiogenomics analysis revealed that the high-risk group exhibited increased cell proliferation and tumour immune suppression. KIT inhibitors may serve as potential therapeutic drugs, whereas ADAM9 and PTK2B are key genes influencing patient prognosis. The artificial intelligence model developed from MRI has emerged as a dependable method for predicting aggressive HCC, with further biological exploration offering the potential to augment its clinical utility.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.